# " a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA)."

> **NCT06602557** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 26 (estimated)

## Conditions studied

- Pneumonia, Bacterial
- Extracorporeal Membrane Oxygenation

## Interventions

- **DRUG:** Amikacin
- **DRUG:** Standard of care

## Key facts

- **NCT ID:** NCT06602557
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-11-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602557, "" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA)."". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06602557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*